PPT-Switch to E/C/F/TAF + DRV
Author : lindy-dunigan | Published Date : 2017-12-09
Study GSUS2920119 ECFTAF DRV 800 mg QD N 89 N 46 Baseline regimen Design Randomisation 2 1 Openlabel Objective Primary Endpoint proportion with treatment success
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Switch to E/C/F/TAF + DRV" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Switch to E/C/F/TAF + DRV: Transcript
Study GSUS2920119 ECFTAF DRV 800 mg QD N 89 N 46 Baseline regimen Design Randomisation 2 1 Openlabel Objective Primary Endpoint proportion with treatment success HIV RNA lt 50 cmL . Wordnetből. nyert szemantikai jegyekkel kombinált keresés a . NooJ. program segítségével. Pajzs Júlia. Nyelvtechnológiai és Alkalmazott Nyelvészeti Osztály. Áttekintés. A felhasznált adatbázisok. SPARE . Study. SPARE Study: switch to DRV/r + RAL . Design. Age ≥ . 20. years. HIV+. HIV-1 RNA. < 50 c/ml > 15 weeks. On LPV/r + TDF/FTC. No prior . virologic. failure. on PI/r- or INSTI-containing regimen. Estudio GS-US-311-1089 . Estudio GS-US-366-1216 . Estudio GS-US-366-1160 . . Diseño. Endpoints. Primario: proporción de pacientes . con C. V . < 50 c/mL a S48 (ITT, . snapshot. ) ; no inferioridad si el margen inferior de IC95% de dos colas para la diferencia = - 8%, poder 85%. GS-US-292-0109 Study. GS-US-311-1089 Study. . Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 (ITT, snapshot) ; non-inferiority if lower margin of a two-sided 95% CI for the difference = -10%, > 95% power. G-103 Ckbeceopap (Pubkop( CO>E) (Last updated December 24, 2019, last reviewed December 24, 2019)Carcinogenicity Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infectio G-143Last updated December 29 2020 last reviewed December 29 2020Animal StudiesCarcinogenicityNo increases in tumor incidence were seen in male and female mice at cobicistat COBI exposures that were 7 in a Single-Tablet Regimen . in Initial HIV-1 Therapy. Combined Primary Results of . Studies GS-US-292-0104 and GS-US-292-0111. David Wohl. 1. , Anton Pozniak. 2. , Melanie Thompson. 3. , Edwin DeJesus. Study 1249. Elvitegravir-Cobicistat-TAF-FTC in HIV/HBV Coinfection . Study 1249: . Design. Source: Gallant J, et al. . J. . Acquir. Immune . Defic. . Syndr. . 2016;73:294-8.. Baseline ART. (n = 72). Study GS-366-1216. Switch from TDF to TAF, each with RPV and FTC. Study GS-366-1216: Design. Source: . Orkin. C et al. Lancet HIV. 2017;4:e195-e204.. *. NOTE. :. of 632 participants randomized, 2 were never treated (630 individuals treated). Supported by an educational grant from Gilead Sciences, Inc.. Gregory D. . Huhn. , MD, MPHTM. COVID-19 Vaccination Coordinator and Senior Director of HIV Services. Cook County Health. Associate Professor, Department of Internal Medicine, Division of Infectious Disease. ADVANCE. . Design. Primary endpoint. Proportion of patients with HIV RNA < 50 c/mL at W48, ITT-E snapshot analysis ; non-inferiority of TFA/FTC if lower margin CI for . the difference = - 10%, 80% power. Study 112. Elvitegravir-Cobicistat-TAF-FTC in Renal Impairment. Study 112: . Design. Source: . Pozniak. A, et al. J . Acquir. Immune . Defic. . Syndr. . 2016;71:530-7.. Baseline ART*. (n = 242). Study Design: Study 112. Associate Dean for Global Health. University of Alabama at Birmingham. Birmingham, Alabama. Cases from the Clinic(. ians. ): . Case. -based Panel Discussion. AU Final: 02/21/17. New York, New York: February 24, 2017. a . tool for assessing applicability and scalability of WASH Technologies for providing sustainable . service delivery. Benedict Tuffuor – . TREND. Regional LA, Ho – 24. th. July, 2013. Uptake [number of units providing services].
Download Document
Here is the link to download the presentation.
"Switch to E/C/F/TAF + DRV"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents